GlyProVac ApS: Financial statements 2020
CVR: 39724758
Source: annual report 2020, Danish Business Authority
01/07/2019 – 30/06/2020
GlyProVac ApS (CVR 39724758) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 1,050,949 and a net result of DKK -698,589 compared with DKK -917,733 the year before. That is an increase of 623.2% compared with the year before. Equity in the 2020 report amounted to DKK 672,278. The solvency ratio was 18.1%. The company had 4 employees in the financial year.
- Gross Profit
- DKK 1,050,949
- Profit/Loss
- DKK -698,589
- Equity
- DKK 672,278
- Total Assets
- DKK 3,713,025
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 1.1 mio. | -699 t. | 672 t. | 4 |
| 2019 | - | 145 t. | -918 t. | 1.4 mio. | 2 |
Official annual report
How creditworthy is GlyProVac ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout GlyProVac ApS
GlyProVac ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Anders Boysen and Ann Zahle Andersen. The board consists of Ann Zahle Andersen (chair), Allan Rosetzsky, Kirsten Winther and Willem Adriaan de Jongh. The company's owners include Bente Kristiansen, Rossi Finans ApS and I/S Rødeledsvej. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -2,128,863 and a net result of DKK -5,168,999 compared with DKK -3,014,952 the year before. Equity in the 2025 report amounted to DKK -831,720.